SPI Infoamtion

Table of Contents

1. Executive Summary: Anti-Obesity Treatments 2009-2024

2. An Introduction to Obesity and its Treatment
2.1 What is Obesity?
2.1.1 Fat is a Necessary Component of the Body
2.1.2 Obesity is a Chronic Disease
2.1.3 Body Weight is Dependent upon Several Factors
2.2 How is Obesity Measured?
2.2.1 Weight-for-Height Tables
2.2.2 Waist Circumference
2.2.3 Body Mass Index (BMI)
2.3 How Serious is the Problem?
2.3.1 Prevalence
2.3.2 Risk Factors of Other Diseases (Co-Morbidities)
2.3.3 Economic Costs
2.4 Historical Causes and Lifestyle Changes
2.4.1 Urbanisation, Modernisation and Economic Development have Contributed to Obesity
2.4.2 Those Most at Risk are Poor in Developed Countries and Wealthy in Developing World
2.5 Factors Causing Obesity
2.5.1 Lifestyle, Environment and Diet
2.5.2 Behaviour
2.5.3 Psychological Factors
2.5.4 Genetics
2.5.5 Antecedent Illnesses and Treatments
2.5.6 Other Causes
2.6 Treatment of Obesity
2.6.1 Lifestyle and Behaviour Changes
2.6.2 Unapproved Drugs
2.6.3 Alternative Therapies
2.6.4 Pharmacotherapy
2.6.5 Surgical Options
2.6.6 Drugs have a Role in the Treatment of Obesity.
2.7 Pharmacotherapy in the Treatment of Obesity
2.7.1 Lipase Inhibitors
2.7.2 Anorectic Drugs
2.7.3 Off-Label Use of Drugs
2.8 Need for Future Development in the Treatment of Obesity
2.8.1 Unmet Needs and Market Potential

3. The World Market for Anti-Obesity Drugs, 2010-2025
3.1 The Current Status and Future Potential of the Anti-Obesity Market
3.2 Leading Companies in the Anti-Obesity Market
3.3 Market History and Current Status
3.3.1 Previous Negative Impacts on the Anti-Obesity Market
3.3.2 The Acomplia Controversy
3.3.3 Phentermine
3.4 Total Anti-Obesity Market Forecast, 2010-2025
3.4.1 Anti-Obesity Treatments Market Growth, 2010-2025
3.5 Xenical Forecast 2010-2025
3.5.1 Xenical Sales Driven Downwards by Generic Competition?
3.5.2 Will Pipeline Drugs Bring More Competition and Drive Xenical Out of the Market?
3.6 Reductil/Meridia Forecast, 2010-2025
3.6.1 Reductil’s Early 2010 Problems
3.6.2 The Impact of Reductil’s Absence from the Anti-Obesity Market
3.7 Alli Forecast 2010-2025
3.7.1 Will Limited Success of Alli Make it Less Susceptible to Generic Competition?
3.7.2 Alli’s Additional Health Benefits Help Market Reputation
3.8 Dinintel Forecast, 2010-2025
3.8.1 History of Dintinel and its Restricted Distribution in the World Market
3.9 Duromine Forecast, 2010-2025
3.9.1 The Resilience of Duromine in the Anti-Obesity Market
3.9.2 Duromine Sales During the Forecast Period
3.10 Total Other Drugs Forecast, 2010-2025
3.10.1 Generic Competitors
3.10.2 New Drug Release: Contrave (Orexigen)
3.10.3 New Drug Release: Lorcaserin (Arena)
3.10.4 New Drug Release: Qnexa (Vivus)
3.10.5 New Drug Release: Liraglutide (Novo Nordisk)
3.10.6 New Drug Release: Empatic/Excalia (Orexigen)
3.11 Market Summary
3.11.1 New Drugs are Refreshing the Market
3.11.2 Lack of Innovation and the Market Opportunity
3.11.3 The Problems with Anorectic Drugs
3.11.4 The Problems with Lipase Inhibitors
3.11.5 The Future of Anti-Obesity Treatments

4. Anti-Obesity Treatments - SWOT Analysis
4.1 Strengths of the Sector
4.1.1 Long-Term Therapy with Anti-Obesity Drugs
4.1.2 Prospects of Multiple Indications for Anti-Obesity Drugs
4.1.3 Off-Label Potential and Competition
4.1.4 The Anti-Obesity Market - Ready for Reinvigoration?
4.1.5 Will Problems with Rimonabant Leave Vacuum in the Market?
4.1.6 New Drugs May Not Fill the Entirety of Customer Needs
4.2 Weaknesses of the Sector
4.2.1 Limited Efficacy of Anti-Obesity Treatments
4.2.2 Undesirable Side-Effects Limit Market Potential of Anti-Obesity Medications
4.2.3 Increased Competition from Both New Drugs and Generic Substitutes
4.2.4 Regulatory Hurdles have Become Stricter
4.2.5 Pharmacotherapy Will Not be the First Line of Treatment
4.3 Opportunities in the Sector
4.3.1 Rising Prevalence Drives Market Potential
4.3.2 Unmet Market Needs - Can Drugs Overcome the Therapeutic Challenges?
4.3.3 A Safe and Effective Anti-Obesity Treatment has Applications in Both the Clinical and Cosmetic Spheres
4.3.4 How the Changing Government Agenda and the High Economic Costs of Obesity Will Drive Growth in the Anti-Obesity Market
4.3.5 Diet and Exercise May be the Mainstay Treatment, but this Approach to Weight Management is Not Always Effective
4.4 Threats to the Sector
4.4.1 Low Reimbursement May Continue to be a Limiting Factor
4.4.2 Long-Term Safety Issues Continue to Stunt Growth
4.4.3 Opinion of Prescribers, the Media and the Public Affects Drug Success and the Success of the Market as a Whole
4.4.4 Healthier Lifestyle Changes May Soon Limit the Current Need for Anti-Obesity Drugs

5. Pipeline Developments in Anti-Obesity Treatments
5.1 Treatments Currently in Phase III
5.1.1 Contrave (Orexigen)
5.1.2 Cetilistat (Alizyme/Takeda
5.1.3 Liraglutide (Novo Nordisk)
5.2 Treatments Currently in Phase II
5.2.1 Empatic/Excalia (Orexigen)
5.2.2 Canagliflozin (Johnson & Johnson)
5.2.3 Obinepitide (7TM Pharma)
5.2.4 Davalinitide (Amylin/Takeda)
5.2.5 BMS 830216 (Bristol-Myers Squibb)
5.2.6 Velneperit (Shionogi)
5.2.7 Sodium Tungstate (Bayer/Barcelona University)
5.2.8 Serglifozin Etabonate (GlaxoSmithKline/Kissei)
5.2.9 Pramlintide & Metreleptin (Amylin)
5.2.10 Hoodia Gordonii Extract (Phytopharm/Council for Scientific and Industrial Research)
5.2.11 MTP Inhibitor (Johnson & Johnson)
5.2.12 TM 30339 (7TM Pharma)
5.2.13 KRP 204 (Kyorin)
5.3 Treatments Currently in Phase I
5.3.1 Trodusquemine (Genaera)
5.3.2 THCV (GW Pharmaceuticals)
5.3.3 Oral PYY3-36 (Emisphere)
5.3.4 AZD 4017 (AstraZeneca)
5.3.5 AZD 6714 (AstraZeneca)
5.3.6 AZD 1656 (AstraZeneca)
5.3.7 NGD 4715 (Neurogen)
5.3.8 OAP 189 (Pfizer)
5.3.9 PF 4325667 (Pfizer)
5.3.10 SRT 2104 (Sirtris/GlaxoSmithKline)
5.3.11 ZYO 1 (Zydus Cadila)
5.3.12 BVT 74316 (Biovitrum)
5.3.13 CP 404 (Compellis/Lousiana State University)
5.3.14 TTP 435 (TransTech)
5.3.15 PRX 07034 (Epix)
5.3.16 PSN 602 (OSI Pharmaceuticals)
5.3.17 TKS 1225 (Wyeth Pharmaceuticals)
5.4 Promising Pipeline Possibilities
5.4.1 Melanotan - The Ultimate Lifestyle Drug?
5.4.2 Increasing Mitochondrial Activity to Increase Energy Expenditure
5.4.3 Inhibiting the Creation of Fat Stores after Gut Absorption

6. Obesity in the Leading World Markets
6.1 The Overall Market for Anti-Obesity Treatments
6.1.1 Drug Development Will Drive the Market
6.2 US Anti-Obesity Market Forecast, 2010-2025
6.2.1 Patent Expiries, FDA Warnings and New Drug Releases Will Create a Turbulent Market
6.2.2 Market Growth During the Forecast Period
6.3 Mexican Anti-Obesity Market Forecast, 2010-2025
6.3.1 The Healthcare System Currently Limits Treatment Accessibility
6.3.2 Prevalence of Obesity is the Primary Factor Driving the Market
6.4 Brazilian Anti-Obesity Market Forecast, 2010-2025
6.4.1 Increasing Prevalence Will Force an Increase in Sales over the Forecast Period
6.5 UK Anti-Obesity Market Forecast, 2010-2025
6.5.1 Lagging Sales and Reductil’s European Woes Will Contribute to Negative Growth in the Early Forecast Period
6.5.2 Government Agenda Will Support Growth of Anti-Obesity Treatments in the UK
6.6 South Korean Anti-Obesity Market Forecast, 2010-2025
6.6.1 Government Agenda Will Maintain High Sales but Momentum Will Dissolve
6.7 Spanish Anti-Obesity Market Forecast, 2010-2025
6.7.1 New Drug Releases and Patent Expiries Will Affect Short Term Growth
6.7.2 The Market Will Show Consistent Positive Growth from 2012 Onwards
6.8 German Anti-Obesity Market Forecast, 2010-2025
6.9 French Anti-Obesity Market Forecast, 2010-2025
6.9.1 Will Reimbursement Drive Sales Growth?
6.10 Total Other Countries Anti-Obesity Market Forecast, 2010-2025
6.10.1 Will Sales Grow Throughout the Forecast Period?
6.10.2 The Impact of Emerging Markets Will Contribute to Other Countries’ Market Growth
6.10.3 Emerging Market: India
6.10.4 Emerging Market: China

7. Experts' Views on the Treatment of Obesity
7.1 Interview with Dr A.M. Sharma, Professor of Medicine and Chair of Obesity Research and Management, University of Alberta, Edmonton, Canada
7.1.1 The Unmet Needs and Obstacles Concerning the Anti-Obesity Market
7.1.2 Obesity is Triggered by Many Factors
7.1.3 Classification of the Disease May Help Combat the Problem
7.1.4 Current Anti-Obesity Treatments
7.1.5 An Alternative Approach: Combination Therapy
7.1.6 Obesity’s Impact on Diabetes
7.1.7 The Politics of Obesity
7.2 Views from Other Experts in the Field
7.2.1 The Most Important Unmet Medical Needs in the Treatment of Obesity
7.2.2 The Future of Anti-Obesity Treatment
7.2.3 Funding of Anti-Obesity Treatments
7.2.4 The Anti-Obesity Market in Developing Nations
7.2.5 Concluding Thoughts

8. Conclusions
8.1 Obesity is a Chronic Disease with Serious Health Effects
8.2 The Prevalence and Economic Costs of Obesity
8.3 The Modern Lifestyle has Contributed Significantly to Obesity
8.4 Obesity is Caused by a Complex Interplay of Factors
8.5 Obesity Treatments and the Role of Pharmaceuticals
8.6 The Unmet Needs and Market Potential for Anti-Obesity Treatments
8.7 The Anti-Obesity Market Will Expand from 2010-2025
8.8 Main Drivers and Restraints for the Anti-Obesity Market
8.9 Geographical Overview of the Anti-Obesity Market
8.10 Outlook for the Future

Appendices
Appendix 1: Conditions Associated with Obesity
Appendix 2: Bariatric Surgery Options
Appendix 3: About Visiongain
Appendix 4: Visiongain Report Evaluation Form

List of Tables
Table 2.1 BMI Classification Bands
Table 2.2 Obesity Prevalence Among US Adults, 1991-2007
Table 3.1 Leading Anti-Obesity Drugs: Sales ($m), Market Shares (%) and Growth (%), 2009
Table 3.2 Leading Companies: Anti-Obesity Drugs, Sales ($m) and Market Shares (%), 2009
Table 3.3 Total Anti-Obesity Market Forecast: Sales ($m) and Growth (%), 2010-2025
Table 3.4 Total Anti-Obesity Market: CAGR Values (%), 2010-2025
Table 3.5 Xenical Forecast Sales ($m) and Growth (%), 2010-2025
Table 3.6 Xenical CAGR Values (%), 2010-2025
Table 3.7 Reductil/Meridia Forecast Sales ($m) and Growth (%), 2010-2025
Table 3.8 Reductil/Meridia CAGR Values (%), 2010-2025
Table 3.9 Alli CAGR Values (%), 2010-2025
Table 3.10 Alli Forecast Sales ($m) and Growth (%), 2010-2025
Table 3.11 Dinintel CAGR Values (%), 2010-2025
Table 3.12 Dinintel Forecast Sales ($m) and Growth (%), 2010-2025
Table 3.13 Duromine CAGR Values (%), 2010-2025
Table 3.14 Duromine Forecast Sales ($m) and Growth (%), 2010-2025
Table 3.15 Total Other Drugs: Forecast Sales ($m) and Growth (%), 2010-2025
Table 3.16 Total Others Drugs: CAGR Values (%), 2010-2025
Table 4.1 SWOT Chart for the Anti-Obesity Market, 2010-2025
Table 5.1 The Anti-Obesity Pipeline, 2010
Table 6.1 US Anti-Obesity Market: Forecast Sales ($m) and Growth (%), 2010-2025
Table 6.2 US Anti-Obesity Market: CAGR Values (%), 2010-2025
Table 6.3 Mexican Anti-Obesity Market: Forecast Sales ($m) and Growth (%), 2010-2025
Table 6.4 Mexican Anti-Obesity Market: CAGR Values (%), 2010-2025
Table 6.5 Brazilian Anti-Obesity Market: CAGR Values (%), 2010-2025
Table 6.6 Brazilian Anti-Obesity Market: Forecast Sales ($m) and Growth (%), 2010-2025
Table 6.7 UK Anti-Obesity Market: Forecast Sales ($m) and Growth (%), 2010-2025
Table 6.8 UK Anti-Obesity Market: CAGR Values (%), 2010-2025
Table 6.9 South Korean Anti-Obesity Market: Forecast Sales ($m) and Growth (%), 2010-2025
Table 6.10 South Korean Anti-Obesity Market: CAGR Values (%), 2010-2025
Table 6.11 Spanish Anti-Obesity Market: Forecast Sales ($m) and Growth (%), 2010-2025
Table 6.12 Spanish Anti-Obesity Market: CAGR Values (%), 2010-2025
Table 6.13 German Anti-Obesity Market: CAGR Values (%), 2010-2025
Table 6.14 German Anti-Obesity Market: Forecast Sales ($m) and Growth (%), 2010-2025
Table 6.15 French Anti-Obesity Market: CAGR Values (%), 2010-2025
Table 6.16 French Anti-Obesity Market: Forecast Sales ($m) and Growth (%), 2010-2025
Table 6.17 Total Other Countries Anti-Obesity Market: Forecast Sales ($m) and Growth (%), 2010-2025
Table 6.18 Total Other Countries Anti-Obesity Market: CAGR Values (%), 2010-2025
Table A2.1 Bariatric Surgery Options

List of Figures
Figure 2.1 Obesity Prevalence Among US Adults, 1991-2007
Figure 3.1 Leading Anti-Obesity Drugs: Sales ($m), 2009
Figure 3.2 Leading Anti-Obesity Drugs: Market Shares (%), 2009
Figure 3.3 Leading Companies: Anti-Obesity Drugs Sales ($m), 2009
Figure 3.4 Leading Companies: Anti-Obesity Market Shares (%), 2009
Figure 3.5 Total Anti-Obesity Market: Sales ($m), 2010-2025
Figure 3.6 Xenical Sales ($m), 2010-2025
Figure 3.7 Reductil/Meridia Sales ($m), 2010-2025
Figure 3.8 Alli Sales ($m), 2010-2025
Figure 3.9 Dinintel Sales ($m), 2010-2025
Figure 3.10 Duromine Sales ($m), 2010-2025
Figure 3.11 Total Other Drugs Sales ($m), 2010-2025
Figure 3.12 Upper Tier Individual Drugs: Sales Forecasts ($m), 2010-2025
Figure 3.13 Lower Tier Individual Drugs: Sales Forecasts ($m), 2010-2025
Figure 6.1 Total Anti-Obesity Market: Sales ($m), 2010-2025
Figure 6.2 US Anti-Obesity Market Forecast: Sales ($m), 2010-2025
Figure 6.3 Mexican Anti-Obesity Market Forecast: Sales ($m), 2010-2025
Figure 6.4 Brazilian Anti-Obesity Market Forecast: Sales ($m), 2010-2025
Figure 6.5 UK Anti-Obesity Market Forecast: Sales ($m), 2010-2025
Figure 6.6 South Korean Anti-Obesity Market Forecast: Sales ($m), 2010-2025
Figure 6.7 Spanish Anti-Obesity Market Forecast: Sales ($m), 2010-2025
Figure 6.8 German Anti-Obesity Market Forecast: Sales ($m), 2010-2025
Figure 6.9 French Anti-Obesity Market Forecast: Sales ($m), 2010-2025
Figure 6.10 Total Other Countries Anti-Obesity Market: Forecast Sales ($m), 2010-2025
Figure 6.11 Anti-Obesity Combined Country Market Forecasts: Sales ($m), 2010-2025
Figure 6.12 Anti-Obesity Market: Country Market Shares (%), 2010-2025
Figure 8.1 Total Anti-Obesity Market: Sales ($m), 2010-2025
Figure 8.2 Anti-Obesity Drugs Forecast: Market Shares (%), 2010-2025
Figure 8.3 Anti-Obesity Combined Country Forecasts: Sales ($m), 2010-2025
Figure 8.4 Anti-Obesity Country Market Shares Forecast, 2010-2025